RE: BUY THE DIP!17 Jun 2022 11:26
So, today she says -Dr Suzy Dilly, CEO of ValiRx commented: "It is important to us at ValiRx to ensure that TheoremRx have sufficient funds to fully progress VAL201 prior to completing the sub-license and committing the project to their care. As such, we have been taking great interest in their progress towards financing. Although the deadline does not expire until 30 June 2022, we are preparing to negotiate to extend this in order to ensure their financing proceeds as expected. Despite a challenging market, the progress we have seen to date is promising and we remain confident that they are the right team for the project."
But kind of contradicts this absolute bunch of lies then, doesn't it? God I hate liars with a passion.
Dr Suzy Dilly, CEO of ValiRx commented: "Although the sub-license of VAL201 to TheoremRx has taken longer to complete than initially anticipated, during the course of the past four months, ValiRx has been continuing to conduct due diligence on TheoremRx and its scientific plans and remains confident that it is well placed to conduct the ongoing development of the VAL201 programme. Our due diligence procedures are now complete and during this FINAL extension of exclusivity we will continue to provide scientific support to TheoremRx's trial start-up processes to ENSURE NO FURTHER DELAYS are encountered."